US2015272921A1PendingUtilityA1

Use of an Omega-3 Lipid-Based Emulsion Following Ischemic Injury to Provide Protection and Recovery in Human Organs

37
Individually held — no corporate assignee on recordPriority: Nov 14, 2005Filed: Jun 12, 2015Published: Oct 1, 2015
Est. expiryNov 14, 2025(expired)· nominal 20-yr term from priority
Inventors:Richard J. DeckelbaumSusan J. Vannucci
A61P 9/10A61K 31/202A61K 35/60A61K 31/22A61K 31/232A61P 25/00A61P 29/00A61K 9/107
37
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides methods of limiting cell death resulting from hypoxic-ischemia comprising, administering an omega-3 lipid-based emulsion after a hypoxic-ischemia insult. The omega-3 lipid-based emulsion preferably comprises at least 20% omega-3 oil, by weight, and wherein the omega-3 oil comprises at least 20% omega-3 triglycerides and/or diglycerides, and wherein fatty acids of the omega-3 trigylceride and/or diglycerides comprise at least 40% EPA and/or DHA. The present invention also provides novel fish-oil compositions for administration after an ischemic insult to limit cell death in the organ that underwent an ischemic event.

Claims

exact text as granted — not AI-modified
1 - 21 . (canceled) 
     
     
         22 . An omega-3 lipid-based emulsion, wherein
 (a) the oil phase of the emulsion consists essentially of omega-3 fish oil or synthetic omega-3 oil or a combination thereof, and the emulsion comprises at least about 10% omega-3 oil by weight in grams per 100 ml of emulsion,   (b) the omega-3 oil comprises at least about 10% omega-3 triglyceride by weight per total weight of the omega-3 oil,   (c) the fatty acid of the omega-3 triglyceride comprises at least about 40% EPA, DHA, or a combination thereof, and   (d) the mean diameter of lipid droplets in the emulsion is from about 100 to 400 nanometers.   
     
     
         23 . The omega-3 lipid-based emulsion of  claim 22 , comprising at least 20% omega-3 oil, by weight in grams per 100 ml of emulsion. 
     
     
         24 . The omega-3 lipid-based emulsion of  claim 22 , comprising about 20% omega-3 oil, by weight in grams per 100 ml of emulsion. 
     
     
         25 . The omega-3 lipid-based emulsion of  claim 22 , wherein the omega-3 oil comprises at least about 10% to about 20% omega-3 triglyceride by weight per total weight of the omega-3 oil. 
     
     
         26 . The omega-3 lipid-based emulsion of  claim 25 , formulated for enteral or parenteral administration. 
     
     
         27 . The omega-3 lipid-based emulsion of  claim 22 , formulated for parenteral administration. 
     
     
         28 . The omega-3 lipid-based emulsion of  claim 22 , wherein the omega-3 oil comprises at least 20% omega-3 triglyceride by weight per total weight of the omega-3 oil. 
     
     
         29 . The omega-3 lipid-based emulsion of  claim 22 , wherein the omega-3 oil comprises about 20% omega-3 triglyceride by weight per total weight of the omega-3 oil. 
     
     
         30 . The omega-3 lipid-based emulsion of  claim 22 , wherein the omega 3-triglyceride comprises about 40% EPA and/or DHA fatty acids. 
     
     
         31 . The omega-3 lipid-based emulsion of  claim 22 , wherein the emulsion comprises at least 20% omega-3 oil by weight in grams per 100 ml of emulsion; the omega-3 oil comprises about 20% omega-3 triglyceride by weight per total weight of the omega-3 oil, and the omega-3 triglyceride comprises at least 40% EPA and/or DHA fatty acids. 
     
     
         32 . A pharmaceutical formulation comprising the omega-3 lipid-based emulsion of  claim 22 . 
     
     
         33 . The omega-3 lipid-based emulsion of  claim 22 , wherein the omega-3 oil is 100% omega-3 triglyceride.

Join the waitlist — get patent alerts

Track US2015272921A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.